Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

Michelle A. Fanale, MD
Published: Wednesday, Mar 29, 2017



Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

The selection of treatments for patients with T-cell lymphoma is a main challenge that is facing this field, states Fanale. When comparing the new agents, they seem to have an overall response rate of 30% to 40% and have complete remission rates between 15% and 20%.

Many of the ongoing clinical trials in this space are attempting to determine which treatment is more suitable for an individual patient through molecular profiling, explains Fanale.
 
SELECTED
LANGUAGE


Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

The selection of treatments for patients with T-cell lymphoma is a main challenge that is facing this field, states Fanale. When comparing the new agents, they seem to have an overall response rate of 30% to 40% and have complete remission rates between 15% and 20%.

Many of the ongoing clinical trials in this space are attempting to determine which treatment is more suitable for an individual patient through molecular profiling, explains Fanale.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x